fda.gov
FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterol
The FDA approved Lipfendra, the first oral PCSK9 inhibitor, for adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia.
